Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
- 17 January 2020
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 87 (3), 347-356
- https://doi.org/10.1002/ana.25680
Abstract
Objective To evaluate the dose‐response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insomnia disorder. Methods Adults (≤64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to receive daily oral placebo, daridorexant (5, 10, 25, or 50 mg), or 10 mg zolpidem for 30 days. The primary efficacy outcome was the change in wake time after sleep onset from baseline to Days 1&2. Secondary outcome measures were change in latency to persistent sleep from baseline to Days 1&2, change in subjective wake time after sleep onset and subjective latency to sleep onset from baseline to Week 4. Safety was also assessed. Results Of 1005 subjects screened, 359 (64% female) were randomized and received ≥1 dose. A significant dose‐response (Multiple Comparison Procedure‐Modelling, two‐sided p<0.001) was found in the reduction of wake after sleep onset and latency to persistent sleep from baseline to Days 1&2 with daridorexant. These reductions were sustained through to Days 28&29 (p=0.050 and p=0.042, respectively). Similar dose‐dependent relationships were observed for subjective wake after sleep onset and subjective latency to sleep onset. The incidence of treatment‐emergent adverse events was 35%, 38%, 38%, and 34% in subjects treated with 5, 10, 25, and 50 mg daridorexant, respectively, compared with 30% for placebo, and 40% for 10 mg zolpidem. There were no clinically‐relevant treatment‐related serious adverse events. Four subjects withdrew due to adverse events. Interpretation Daridorexant induced a dose‐dependent reduction in wake time after sleep onset in subjects with insomnia disorder. Clinicaltrials.gov (NCT02839200)Keywords
This publication has 26 references indexed in Scilit:
- Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated EventsSleep Medicine, 2012
- Insomnia in central neurologic diseases – Occurrence and managementSleep Medicine Reviews, 2011
- The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and AdultsAmerican Journal of Psychiatry, 2011
- Insomnia in patients with neurodegenerative conditionsSleep Medicine, 2007
- Design and Analysis of Dose-Finding Studies Combining Multiple Comparisons and Modeling ProceduresJournal of Biopharmaceutical Statistics, 2006
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response StudiesBiometrics, 2005
- Validation of the Insomnia Severity Index as an outcome measure for insomnia researchSleep Medicine, 2001
- The measurement of disabilityInternational Clinical Psychopharmacology, 1996
- The benzodiazepine withdrawal symptom questionnaireJournal of Affective Disorders, 1990
- Subjective and Objective Sleepiness in the Active IndividualInternational Journal of Neuroscience, 1990